MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stock Holdings in BioNTech SE (NASDAQ:BNTX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. cut its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 16.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,415 shares of the company's stock after selling 5,837 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in BioNTech were worth $3,466,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BNTX. Jones Financial Companies Lllp increased its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its stake in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares during the last quarter. Allianz SE acquired a new stake in BioNTech during the fourth quarter worth about $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new position in BioNTech during the fourth quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC acquired a new position in BioNTech in the fourth quarter valued at approximately $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Morgan Stanley dropped their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, Citigroup restated a "buy" rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $141.73.

BioNTech Price Performance

Shares of BioNTech stock traded down $0.39 during mid-day trading on Friday, reaching $98.68. 598,406 shares of the stock traded hands, compared to its average volume of 923,945. The stock has a market capitalization of $23.72 billion, a PE ratio of -46.99 and a beta of 1.35. The business has a 50-day moving average of $97.40 and a 200 day moving average of $108.53. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 earnings per share. On average, analysts predict that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.